
On Thursday, President Donald Trump announced the third agreement with a pharmaceutical manufacturer to bring American drug prices in line with the lowest paid by other developed nations, known as the most-favored-nation, or MFN price.
The agreement is with EMD Serono, a unit of Merck KGaA (OTC:MKGAF) (OTC:MKKGY), for its fertility treatments, resulting in substantial cost savings on fertility treatments, including: